Semaglutide still the GLP-1 heavyweight If Novo Nordisks semaglutide were counted as a single drug, it would be second bestselling drug of 2023, with total sales of $19.93 billion compared to Keytrudas (pembrolizumab) $25.01 billion
Interestingly, flavonol and phenolic acid derivatives molecules are taking the most attention as these possess several biochemical responses [12-14]
The brand also emphasizes sustainability and global accessibility , with a growing international fanbase and glowing reviews from wellness enthusiasts
ALC reduces pro-inflammatory cytokines and lowers inflammatory markers [161]
N c xem nh l chic nam chm ht ly cc gc t do, cc loi kim loi nng v c t c hp th mi ngy qua da, hi th, nc ung, thc phm kch thch o thi chng ra khi c th, gi cho c th lun khe mnh, tr p